[go: up one dir, main page]

SG170047A1 - Nanoparticulate posaconazole formulations - Google Patents

Nanoparticulate posaconazole formulations

Info

Publication number
SG170047A1
SG170047A1 SG201101417-2A SG2011014172A SG170047A1 SG 170047 A1 SG170047 A1 SG 170047A1 SG 2011014172 A SG2011014172 A SG 2011014172A SG 170047 A1 SG170047 A1 SG 170047A1
Authority
SG
Singapore
Prior art keywords
nanoparticulate posaconazole
nanoparticulate
posaconazole
posaconazole formulations
particles
Prior art date
Application number
SG201101417-2A
Other languages
English (en)
Inventor
Scott Jenkins
Gary Liversidge
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of SG170047A1 publication Critical patent/SG170047A1/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J37/00—Discharge tubes with provision for introducing objects or material to be exposed to the discharge, e.g. for the purpose of examination or processing thereof
    • H01J37/26—Electron or ion microscopes; Electron or ion diffraction tubes
    • H01J37/28—Electron or ion microscopes; Electron or ion diffraction tubes with scanning beams

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Manufacturing & Machinery (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG201101417-2A 2006-05-30 2007-05-22 Nanoparticulate posaconazole formulations SG170047A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80896106P 2006-05-30 2006-05-30

Publications (1)

Publication Number Publication Date
SG170047A1 true SG170047A1 (en) 2011-04-29

Family

ID=38610087

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201101417-2A SG170047A1 (en) 2006-05-30 2007-05-22 Nanoparticulate posaconazole formulations

Country Status (16)

Country Link
US (1) US20070281011A1 (fr)
EP (2) EP2040675A1 (fr)
JP (1) JP2009538927A (fr)
KR (1) KR20090015994A (fr)
CN (1) CN101495096A (fr)
AR (1) AR063940A1 (fr)
AU (1) AU2007256983A1 (fr)
BR (1) BRPI0712130A2 (fr)
CA (1) CA2653504A1 (fr)
IL (1) IL195524A0 (fr)
MX (1) MX2008015275A (fr)
NZ (1) NZ573555A (fr)
SG (1) SG170047A1 (fr)
TW (1) TW200811145A (fr)
WO (1) WO2007143390A1 (fr)
ZA (1) ZA200809971B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE489062T1 (de) 2003-09-12 2010-12-15 Z Medica Corp Teilweise hydriertes hämostatisches mittel
US20060178609A1 (en) 2005-02-09 2006-08-10 Z-Medica, Llc Devices and methods for the delivery of molecular sieve materials for the formation of blood clots
CA2597940A1 (fr) 2005-02-15 2006-08-24 Virginia Commonwealth University Technologies minerales pour une hemostase aigue et pour le traitement de lesions aigues et d'ulceres chroniques
US8938898B2 (en) 2006-04-27 2015-01-27 Z-Medica, Llc Devices for the identification of medical products
US7968114B2 (en) 2006-05-26 2011-06-28 Z-Medica Corporation Clay-based hemostatic agents and devices for the delivery thereof
US7604819B2 (en) 2006-05-26 2009-10-20 Z-Medica Corporation Clay-based hemostatic agents and devices for the delivery thereof
US8202532B2 (en) 2006-05-26 2012-06-19 Z-Medica Corporation Clay-based hemostatic agents and devices for the delivery thereof
US20080125686A1 (en) * 2006-11-29 2008-05-29 Denny Lo Heat mitigating hemostatic agent
EP2095816A1 (fr) * 2008-02-29 2009-09-02 Schlichthaar, Rainer, Dr. Nanosuspension avec médication antifongique à administrer via inhalation avec une sécurité et un profil d'impureté améliorés
SG10201403986UA (en) * 2008-04-15 2014-10-30 Merck Sharp & Dohme High Density Compositions Containing Posaconazole And Formulations Comprising The Same
EP2130540A1 (fr) 2008-06-02 2009-12-09 Sandoz AG Compositions pharmaceutiques contenant une forme cristalline du posaconazole
WO2010138539A2 (fr) 2009-05-27 2010-12-02 Elan Pharma International Ltd. Réduction de l'agrégation à l'origine de paillettes dans des compositions à base d'un principe actif nanoparticulaire
EP2498903A4 (fr) * 2009-11-09 2013-10-30 Univ Texas Procédé utilisant une matrice d'émulsion pour former de petites particules d'agents hydrophobes avec un caractère hydrophile enrichi en surface par congélation ultra-rapide
BR112012029225B1 (pt) 2010-05-19 2020-10-27 Sandoz Ag processo para a preparação de um composto quiral, composto quiral e uso de um composto quiral
MX2012013331A (es) 2010-05-19 2013-02-01 Sandoz Ag Purificacion de posaconazol y de intermediarios de posaconazol.
BR112012029227B1 (pt) 2010-05-19 2020-01-07 Sandoz Ag Processo para a preparação de um composto quiral, composto quiral e uso de um composto
CN102892762B (zh) 2010-05-19 2016-04-20 桑多斯股份公司 制备泊沙康唑中间体
DK3391890T3 (da) * 2010-06-29 2021-11-01 Merck Sharp & Dohme Intravenøse posaconazolopløsningsformuleringer, der er stabiliseret ved hjælp af substitueret beta-cyclodextrin
US8858969B2 (en) 2010-09-22 2014-10-14 Z-Medica, Llc Hemostatic compositions, devices, and methods
CA2838051C (fr) 2011-06-16 2019-09-24 Sandoz Ag Procede pour la preparation d'un compose chiral
CA2874797A1 (fr) * 2012-06-14 2013-12-19 Sandoz Ag Composition pharmaceutique comprenant du posaconazole cristallin
KR102375103B1 (ko) 2012-06-22 2022-03-16 지-메디카 엘엘씨 지혈 장치
EP2964198A2 (fr) * 2013-03-04 2016-01-13 vTv Therapeutics LLC Compositions stables d'activateur de glucokinase
CN104173350A (zh) * 2013-05-27 2014-12-03 正大天晴药业集团股份有限公司 含泊沙康唑的药物组合物及制备方法
US20150231081A1 (en) * 2014-02-20 2015-08-20 Cadila Healthcare Limited Delayed release posaconazole tablets
CN104971045A (zh) * 2014-04-11 2015-10-14 上海宣泰医药科技有限公司 泊沙康唑药物组合物及其制备方法和药物制剂
CN105012227A (zh) * 2014-04-29 2015-11-04 北京济美堂医药研究有限公司 一种提高溶出的抗真菌组合物及其制备方法
TWI535784B (zh) 2014-08-26 2016-06-01 財團法人工業技術研究院 剪切增稠配方、及包含其之複合材料
EP4424308A3 (fr) * 2016-02-26 2024-12-04 Alfred E. Tiefenbacher (GmbH & Co. KG) Formulation gastro-résistante contenant du posaconazole et un inhibiteur de précipitation polymère
CN105997872B (zh) * 2016-07-08 2019-02-19 河南省立眼科医院 一种含有泊沙康唑的眼用纳米胶束抗真菌溶液
NZ752353A (en) * 2016-10-14 2023-06-30 Pulmatrix Operating Co Inc Antifungal dry powders
TR201620462A2 (tr) 2016-12-31 2018-07-23 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
CN109745299A (zh) * 2017-11-07 2019-05-14 郑州泰丰制药有限公司 一种泊沙康唑水凝胶贴剂及其制备方法
TR201722493A2 (tr) * 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Posakonazol i̇çeren kati farmasöti̇k kompozi̇syon
CN109260148A (zh) * 2018-10-18 2019-01-25 南京安伦化工科技有限公司 一种高纯度泊沙康唑悬浮液的制备方法
CN110974787B (zh) * 2019-12-31 2023-04-07 浙江普利药业有限公司 泊沙康唑干混悬剂及其制备方法
CN115721601A (zh) * 2022-11-23 2023-03-03 无锡福祈制药有限公司 一种泊沙康唑纳米晶口服固体药物组合物及其制备方法
CN117545470A (zh) * 2023-09-18 2024-02-09 北京德立福瑞医药科技有限公司 泊沙康唑固体分散体及其制备方法

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4783484A (en) 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
US4885310A (en) * 1985-05-09 1989-12-05 Gerald N. Kern Anti-fungal methods and agent
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
EP0593627A1 (fr) * 1991-07-05 1994-04-27 The University Of Rochester Particules poreuses non agregees ultra-petites piegant des bulles gazeuses
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5349957A (en) * 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5401492A (en) * 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5264610A (en) * 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5525328A (en) * 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5593657A (en) * 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5500204A (en) * 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5543133A (en) * 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
CA2213638C (fr) * 1995-02-24 2004-05-04 Nanosystems L.L.C. Aerosols contenant des dispersions de nanoparticules
US5643552A (en) * 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) * 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
JP5038552B2 (ja) 1995-10-17 2012-10-03 オバン・エナジー・リミテッド 不溶性薬物の送達
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998035666A1 (fr) * 1997-02-13 1998-08-20 Nanosystems Llc Preparation de pastilles de naproxene nanoparticulaire
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
EP2266542A3 (fr) 1998-10-01 2013-07-31 Elan Pharma International Limited Libération regulée de compositions nanoparticulaires
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US20040141925A1 (en) 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6641565B1 (en) 1998-11-13 2003-11-04 Elan Pharma International Limited drug delivery systems and methods
US7376728B1 (en) * 2000-07-25 2008-05-20 Ricoh Company, Ltd. Method and system for monitoring, collecting information, diagnosing and servicing a remote system
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
AU5300000A (en) * 1999-06-01 2000-12-18 Elan Pharma International Limited Small-scale mill and method thereof
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
ES2334435T3 (es) 2000-04-26 2010-03-10 Elan Pharma International Limited Aparato de molienda humeda higienica.
US20040156872A1 (en) 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
US7998507B2 (en) 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
EP1372394A1 (fr) 2001-04-03 2004-01-02 Schering Corporation Composition antifongique a biodisponibilite accrue
PT1392441E (pt) 2001-06-05 2008-09-30 Elan Pharma Int Ltd Sistema e método para trituração de materiais
DE60203506T2 (de) * 2001-06-22 2006-02-16 Marie Lindner Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics
US20030095928A1 (en) 2001-09-19 2003-05-22 Elan Pharma International Limited Nanoparticulate insulin
EP1443912B1 (fr) 2001-10-12 2007-08-29 Elan Pharma International Limited Compositions combinant des caracteristiques de liberation immediate et de liberation prolongee
CA2475092C (fr) 2002-02-04 2012-05-01 Christian F. Wertz Compositions nanoparticulaires a stabilisateur superficiel de lysozyme
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
CA2479665C (fr) 2002-03-20 2011-08-30 Elan Pharma International Ltd. Compositions nanoparticulaires d'inhibiteurs d'angiogenese
DE60319073T2 (de) 2002-03-20 2009-02-05 Elan Pharma International Ltd. Nanopartikelzusammensetzungen von mitogen-aktivierten protein (map) kinase inhibitoren
WO2003080023A2 (fr) 2002-03-20 2003-10-02 Elan Pharma International Limited Formes posologiques a dissolution rapide presentant une friabilite reduite
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
EP1503737B1 (fr) 2002-05-06 2009-01-07 Elan Pharma International Limited Formulations de nystatine nanoparticulaires
EP1511467A1 (fr) 2002-06-10 2005-03-09 Elan Pharma International Limited Formulation de polycosanol nanoparticulaires et nouvelles combinaisons de polycosanol
JP2005531606A (ja) 2002-06-10 2005-10-20 エラン ファーマ インターナショナル，リミティド ナノ粒子ステロール製剤およびステロールの組合せ
CA2492488A1 (fr) 2002-07-16 2004-01-22 Elan Pharma International, Ltd. Compositions pour doses liquides d'agents actifs nanoparticulaires stables
ATE487470T1 (de) 2002-09-11 2010-11-15 Elan Pharma Int Ltd Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse
WO2004026303A2 (fr) * 2002-09-23 2004-04-01 Schering Corporation Traitement d'infections fongiques
JP2006501936A (ja) * 2002-10-04 2006-01-19 エラン ファーマ インターナショナル，リミティド 固体ナノ粒子活性薬剤のガンマ線照射
ATE514418T1 (de) 2002-11-12 2011-07-15 Elan Pharma Int Ltd Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
CA2513064C (fr) 2003-01-31 2009-11-10 Elan Pharma International, Ltd. Formulations contenant des nanoparticules de topiramate
US20040208833A1 (en) 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
EP1617818A1 (fr) * 2003-04-29 2006-01-25 Baxter International Inc. Formulation destinee a rendre un medicament antimicrobien efficace contre des organismes normalement consideres comme etant resistant a ce medicament
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
EP1651189B1 (fr) 2003-08-08 2008-12-03 Elan Pharma International Limited Nouvelles compositions de metaxalone
CA2544627A1 (fr) 2003-11-05 2005-05-19 Elan Pharma International Ltd. Compositions nanoparticulaires comprenant un peptide comme stabilisant de surface
US20050147664A1 (en) 2003-11-13 2005-07-07 Elan Pharma International Ltd. Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
US20060009469A1 (en) * 2004-05-28 2006-01-12 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmacutical compositions of posaconazole
EA200701065A1 (ru) 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
WO2006063078A2 (fr) 2004-12-08 2006-06-15 Elan Corporation, Plc Composition pharmaceutique de topiramate
MX2007007342A (es) 2004-12-15 2007-12-11 Elan Pharma Int Ltd Formulaciones de tacrolimus nanoparticuladas.
US20060159767A1 (en) 2004-12-22 2006-07-20 Elan Pharma International Limited Nanoparticulate bicalutamide formulations
CN101132770A (zh) 2005-01-06 2008-02-27 伊兰制药国际有限公司 纳米微粒坎地沙坦制剂
EP1838701A1 (fr) 2005-01-18 2007-10-03 Elan Pharmaceuticals Inc. Sulfamides heterocycliques n-substitues
MX2007009915A (es) 2005-02-15 2007-11-06 Elan Pharma Int Ltd Formulaciones en aerosol e inyectables de benzodiazepina nanoparticulada.
MX2007010394A (es) 2005-02-24 2008-02-19 Elan Pharma Int Ltd Formulaciones nanoparticuladas de docetaxel y analogos del mismo.
US20060204588A1 (en) 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
CN101175480A (zh) * 2005-03-16 2008-05-07 伊兰制药国际有限公司 纳米微粒白三烯受体拮抗剂/皮质类固醇制剂
EP1868576A2 (fr) 2005-03-17 2007-12-26 Elan Pharma International Limited Compositions injectables de composes nanoparticulaires immunosuppresseurs
BRPI0606280A2 (pt) 2005-03-17 2009-06-09 Elan Pharma Int Ltd composições de bisfosfonato nanoparticulado
CA2602341A1 (fr) 2005-03-23 2006-09-28 Elan Pharma International Limited Formulations d'un corticosteroide nanoparticulaire et d'un antihistamine
WO2006110809A2 (fr) 2005-04-12 2006-10-19 Elan Pharma International, Limited Formulations inhibitrices de lipase nanoparticulaire
EP1871345B1 (fr) 2005-04-12 2012-08-01 Elan Pharma International Limited Formules de nanoparticules d'erlotinib
BRPI0608771A2 (pt) * 2005-05-10 2010-01-26 Elan Pharma Int Ltd formulações de clopidogrel em nanopartìcula
AU2006309295B2 (en) 2005-06-03 2012-04-26 Elan Pharma International Limited Nanoparticulate acetaminophen formulations
ATE459341T1 (de) 2005-06-03 2010-03-15 Elan Pharma Int Ltd Nanoteilchenförmige imatinib-mesylat- formulierungen
US20070042049A1 (en) 2005-06-03 2007-02-22 Elan Pharma International, Limited Nanoparticulate benidipine compositions
JP2008543766A (ja) * 2005-06-09 2008-12-04 エラン ファーマ インターナショナル リミテッド ナノ粒子エバスチン製剤
BRPI0611626A2 (pt) 2005-06-13 2010-09-21 Elan Pharma Int Ltd formulações da combinação de nanopartìculas de clopidogrel e aspirina
CA2614412A1 (fr) 2005-07-07 2007-01-18 Elan Pharma International, Limited Formulations de clarithromycine nanoparticulaires
JP2009507925A (ja) 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤

Also Published As

Publication number Publication date
NZ573555A (en) 2012-09-28
JP2009538927A (ja) 2009-11-12
AR063940A1 (es) 2009-03-04
EP2040675A1 (fr) 2009-04-01
BRPI0712130A2 (pt) 2012-01-17
US20070281011A1 (en) 2007-12-06
ZA200809971B (en) 2009-08-26
EP2343053A1 (fr) 2011-07-13
WO2007143390A1 (fr) 2007-12-13
AU2007256983A1 (en) 2007-12-13
CA2653504A1 (fr) 2007-12-13
KR20090015994A (ko) 2009-02-12
IL195524A0 (en) 2009-09-01
CN101495096A (zh) 2009-07-29
TW200811145A (en) 2008-03-01
MX2008015275A (es) 2009-02-06

Similar Documents

Publication Publication Date Title
SG170047A1 (en) Nanoparticulate posaconazole formulations
WO2008008733A3 (fr) Formulations de sorafenib nanoparticulaire
WO2007086914A3 (fr) Formulations de nanoparticules de clopidogrel
WO2007033239A3 (fr) Formulations nanoparticulaires de tadalafil
WO2007053197A3 (fr) Preparations nanoparticulaires a base d'acetaminophene
WO2007008537A3 (fr) Formulations de clarithromycine nanoparticulaires
WO2008092006A3 (fr) Compositions antimicrobiennes
NO20080202L (no) Nanopartikulaere clopidogrel og aspirin kombinasjonsformuleringer
EP1895984B8 (fr) Formulations d'imatinib mesylate nanoparticulaires
WO2007035348A3 (fr) Formulations aripiprazoliques nanoparticulaires
NO20073559L (no) Nanopartiklulaere tacrolimus-formuleringer
NZ595904A (en) A novel formulation of meloxicam
NZ595987A (en) A novel formulation of diclofenac
MY159208A (en) A novel formulation of indomethacin
NZ600231A (en) Pharmaceutical compositions comprising sigma receptor ligands
WO2009041787A3 (fr) Composition pharmaceutique comprenant des inhibiteurs de molécule d'adhérence cellulaire isolée de piper nigrum pour la prévention et le traitement de maladies inflammatoires
WO2008062475A3 (fr) Compositions pharmaceutiques d'ursodiol
MY161103A (en) 5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide and salts thereof as hdl cholesterol raising agents
WO2006138421A3 (fr) Formulations d'azelnidipine nanoparticulaire
WO2009041786A3 (fr) Composition pharmaceutique comprenant des inhibiteurs de molécule d'adhérence cellulaire isolée de piper longum pour la prévention et le traitement de maladies inflammatoires
WO2007146943A3 (fr) Formulations d'inhibiteurs de kinase nanoparticulaires
WO2006135689A3 (fr) Formulations d'ebastine nanoparticulaire
HK1117060A1 (en) Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
GB2442366A (en) Nanoparticulate and controlled release compositions comprising prostaglandin derivatives
MY153292A (en) Benzimidazole carbamate composition